A Bioequivalence Study of Netupitant/Palonosetron Oral Suspension versus Hard Capsules in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of an oral suspension formulation of the netupitant/palonosetron combination product compared to its hard capsule counterpart. This assessment is conducted following a single-dose administration in healthy male and female volunteers. Establishing bioequivalence is clinically relevant as it ensures that the new formulation provides the same therapeutic effect and safety profile as the existing formulation, which is crucial for patient safety and treatment efficacy.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range for participants is categorized as adults, specifically between 18 to 65 years. The trial does not focus on a vulnerable population, and the selection criteria for participants have not been disclosed by the sponsor. The total number of participants involved in the study has not been provided. Lifestyle considerations such as diet, physical activity, or habits have not been specified. The sponsor has not provided detailed information regarding key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **bioequivalence** of an oral suspension of a netupitant/palonosetron combination product compared to its hard capsule form. This study is conducted in an open-label, randomized, single-center, two-treatment, four-period, two-sequence replicative design. The trial involves healthy male and female volunteers and is categorized as a Phase 2 study. The estimated recruitment start date is September 18, 2023, with an anticipated end date of March 26, 2024, indicating a total trial duration of approximately six months.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as the screening phase to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into one of the two treatment sequences. The study involves multiple dosing periods, during which participants will receive either the oral suspension or the hard capsule formulation. Each dosing period will be followed by a washout phase to ensure no carryover effects between treatments. Follow-up visits will be scheduled to monitor the participants' health and collect necessary data for bioequivalence analysis.

The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather any remaining data. The expected length of participant involvement is contingent upon the completion of all dosing and follow-up visits, typically spanning several weeks. Conditions that may lead to early termination from the study include adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The study is structured to maintain scientific rigor and ensure the reliability of the results, adhering to ethical standards and regulatory requirements.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on September 18, 2023, with an estimated end date of March 26, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to standard clinical trial protocols to ensure the accuracy and reliability of the efficacy assessments. The study will be conducted in accordance with regulatory requirements and ethical guidelines to ensure the integrity of the data collected.